Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 19, 2026 07:33 ET | Source: Research and Markets

Radioligand Therapy Market to Surge with 13.1% CAGR: Projected Growth from $2.6B in 2025 to $4.8B by 2030 - Novartis' Pluvicto and Lutathera Have Catalyzed Commercial Momentum

Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Radioligand Therapeutics in Cancer Treatment: Global Markets" has been added to ResearchAndMarkets.com's offering.The global market for radioligand...
February 19, 2026 01:00 ET | Source: IBA SA

IBA et Shreeji signent un accord pour quatre cyclotrons afin d’étendre la production de radiopharmaceutiques TEP en Inde

Louvain-la-Neuve, Belgium – 19 février 2026 – IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d'accélérateurs de particules et acteur de premier plan en médecine...
February 19, 2026 01:00 ET | Source: IBA SA

IBA and Shreeji sign multi‑site agreement for four cyclotrons to expand PET radiopharmaceutical manufacturing across India

Louvain-la-Neuve, Belgium – 19 February 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology with a preeminent position in nuclear medicine, and...
February 17, 2026 07:18 ET | Source: ICPO Foundation

Prof. Lalith Kumar Shiyam Sundar, LMU Klinikum München, erhielt den ICPO Research Grant für „KI-gestützte Fortschritte in der Präzisionsonkologie“

Sein Projekt wird von der ICPO Foundation mit 100.000 Euro gefördert und wurde aus 18 hochkarätigen Bewerbungen aus zwölf Ländern ausgewählt. 17. Februar 2026 – Wiesbaden, Deutschland. Die...
February 17, 2026 07:18 ET | Source: ICPO Foundation

Prof. Lalith Kumar Shiyam Sundar, LMU Hospital Munich, received the ICPO Research Grant for “AI-driven Advancements in Precision Oncology”

Prof. Lalith Kumar Shiyam Sundar, LMU Hospital Munich, received the Research Grant for “AI-driven Advancements in Precision Oncology” from ICPO Foundation
February 04, 2026 01:30 ET | Source: Curium

Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of Lu-PSMA-I&T for Prostate Cancer in Japan

A Registrational Phase 2 clinical trial has been initiated in Japan for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE)...
January 28, 2026 12:28 ET | Source: Memorial Health Group

Memorial Şişli Hospital Earns EARL “Theranostics Center of Excellence” for Nuclear Oncology Treatments

Memorial Sisli Hospital’s Nuclear Medicine Department has been recognized as an EARL-qualified Theranostics Center of Excellence by EANM.
December 19, 2025 01:00 ET | Source: IBA SA

Avec l’acquisition d’ORA, IBA renforce son leadership stratégique en médecine nucléaire

Louvain-la-Neuve, Belgique, le 19 décembre 2025 - IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélération de particules et acteur de premier plan en médecine...
December 19, 2025 01:00 ET | Source: IBA SA

IBA acquires ORA expanding its strategic leadership in Nuclear Medicine

Louvain-La-Neuve, Belgium, 19 December 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology with a preeminent position in nuclear medicine, acquires...
December 03, 2025 04:04 ET | Source: Curium

Curium Establishes Legal Entity in China

Curium has established a legal entity in China which represents a major milestone in Curium’s international growth strategy and will enhance Curium’s ability to serve patients with cancer across...